Business Wire

TAKEDA-PHARMACEUTICAL

18.1.2024 13:01:33 CET | Business Wire | Press release

Share
Takeda Named Global Top Employer for Seventh Consecutive Year

Takeda (TSE:4502/NYSE:TAK) today announced that for the seventh consecutive year, it has received global Top Employer® certification for 2024. Takeda is one of just 17 companies that received global recognition, and it was additionally certified as a Top Employer across 24 countries.

The Top Employers Institute program certifies organizations based on the participation and results of their HR Best Practices Survey. This survey covers 20 topics including people strategy, work environment, talent acquisition, learning, diversity & inclusion, well-being and more. Companies are evaluated on existing policies and practices.

“Our colleagues work hard to help patients around the world, which is why we focus on creating an exceptional people experience at Takeda,” said Lauren Duprey, chief human resources officer, Takeda. “Receiving this recognition from Top Employers Institute confirms that prioritizing talent, well-being, learning and diversity, equity and inclusion is the right approach – and that by doing so, we’re enabling our people to discover and deliver life-transforming treatments around the globe.”

“Exceptional times bring out the best in people and organizations, and we have witnessed this in our Top Employers Certification Program this year: an exceptional performance from the certified Top Employers 2024. Amongst this community of outstanding organizations, Takeda, has proven their commitment to their employees on a global scale,” said David Plink, chief executive officer, Top Employers Institute. “This consistency in people practices across the globe characterizes an exclusive group of companies that have achieved a global certification through the Top Employers Program. We are proud to announce and celebrate these companies and their achievement in 2024.”

Takeda excelled globally in the areas of ethics & integrity, purpose & values, business strategy, employer branding and organization & change. The full list of countries where Takeda was named a Top Employer is below:

  • Asia Pacific: Australia, China, India, Japan, South Korea
  • Europe: Austria, Czech Republic, France, Germany, Ireland, Italy, Poland, Portugal, Slovakia, Spain, Switzerland, United Kingdom
  • Latin America: Argentina, Brazil, Colombia, Mexico
  • Middle East: Israel
  • North America: Canada and United States

To learn more about Top Employers Institute and the Top Employers certification, please visit: https://www.top-employers.com.

About Takeda

Takeda is focused on creating better health for people and a brighter future for the world. We aim to discover and deliver life-transforming treatments in our core therapeutic and business areas, including gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines. Together with our partners, we aim to improve the patient experience and advance a new frontier of treatment options through our dynamic and diverse pipeline. As a leading values-based, R&D-driven biopharmaceutical company headquartered in Japan, we are guided by our commitment to patients, our people and the planet. Our employees in approximately 80 countries and regions are driven by our purpose and are grounded in the values that have defined us for more than two centuries. For more information, visit www.takeda.com.

Important Notice

For the purposes of this notice, “press release” means this document, any oral presentation, any question and answer session and any written or oral material discussed or distributed by Takeda Pharmaceutical Company Limited (“Takeda”) regarding this release. This press release (including any oral briefing and any question-and-answer in connection with it) is not intended to, and does not constitute, represent or form part of any offer, invitation or solicitation of any offer to purchase, otherwise acquire, subscribe for, exchange, sell or otherwise dispose of, any securities or the solicitation of any vote or approval in any jurisdiction. No shares or other securities are being offered to the public by means of this press release. No offering of securities shall be made in the United States except pursuant to registration under the U.S. Securities Act of 1933, as amended, or an exemption therefrom. This press release is being given (together with any further information which may be provided to the recipient) on the condition that it is for use by the recipient for information purposes only (and not for the evaluation of any investment, acquisition, disposal or any other transaction). Any failure to comply with these restrictions may constitute a violation of applicable securities laws.

The companies in which Takeda directly and indirectly owns investments are separate entities. In this press release, “Takeda” is sometimes used for convenience where references are made to Takeda and its subsidiaries in general. Likewise, the words “we,” “us” and “our” are also used to refer to subsidiaries in general or to those who work for them. These expressions are also used where no useful purpose is served by identifying the particular company or companies.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240118372418/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

HistoSonics Opens Expanded Histotripsy Training Center in Hong Kong20.7.2026 14:00:00 CEST | Press release

HistoSonics today announced the opening of its expanded Histotripsy Training Center in Hong Kong, reinforcing the city's position as a leading hub for physician education, clinical collaboration, and innovation in Asia. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260720812810/en/ Pictured at the expanded Histotripsy Training Center in Hong Kong. Front row (left to right): Dr. Angus Yuen, Chief Medical Officer, Gleneagles Hospital Hong Kong; Prof. Albert Chan, Director of Liver Cancer Surgery Centre, Gleneagles Hospital Hong Kong; Dr. Kenneth Tsang, Regional Chief Executive Officer, IHH Healthcare North Asia, and Chief Executive Officer, Gleneagles Hospital Hong Kong; Dr. Vince Lau, Director of Interventional Radiology Centre, Gleneagles Hospital Hong Kong; Dr. Joe Herman, Vice President, Medical Affairs, HistoSonics. Back row (left to right): Jay Lee, APAC Regional Manager, HistoSonics; Eric Kwong, Hong Kong Sales Manager

Shaping a Generation Through Dialogue: Inside the Doha Debates Ambassador Program20.7.2026 13:29:00 CEST | Press release

Applications are open for young people from around the world to learn to engage and lead through truth-seeking conversations about complex global issues In a world shaped by change and competing narratives, the ability to listen, question and engage in constructive dialogue has never been more critical. Through the Doha Debates Ambassador Program, a production of Qatar Foundation, young people from around the world are not only learning these skills, but actively applying them in their communities, careers and areas of study. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260720452437/en/ Shaping a Generation Through Dialogue: Inside the Doha Debates Ambassador Program. Applications are open for young people from around the world to learn to engage and lead through truth-seeking conversations about complex global issues. (Photo: AETOSWire) This online educational program teaches young people from across the globe to debate d

Kinaxis Appoints Herb Yeh as Chief Financial Officer and Chief Strategy Officer20.7.2026 13:01:00 CEST | Press release

Seasoned corporate finance veteran brings more than 25 years of experience working with enterprise software companies through growth, M&A, and strategic transformation Kinaxis® Inc. (TSX:KXS), a global leader in supply chain planning and orchestration, today announced the appointment of Herb Yeh as Chief Financial Officer and Chief Strategy Officer, effective July 27, 2026. In this role, Yeh will oversee the global finance organization and corporate strategy operations at Kinaxis, leading all Finance, Accounting, Investor Relations, Corporate Strategy, and Corporate Development. He will work closely with the executive leadership team and Board of Directors to support disciplined execution, long-term growth, and shareholder value creation. "Herb has spent his career working with boards and management teams at their most critical inflection points in enterprise software, and we are thrilled to have him join Kinaxis," said Razat Gaurav, Chief Executive Officer of Kinaxis. "He has followed

IFF Announces Agreement to Sell Its Portfolio of Botanical Extracts, Vitamins & Minerals and Food Enhancement Activities to SuanNutra, a Portfolio Company of Carbyne Equity Partners.20.7.2026 12:45:00 CEST | Press release

IFF (NYSE: IFF) — a global leader in flavors, fragrances, and health and biosciences — today announced that it has entered into an agreement with SuanNutra, a Carbyne Equity Partners portfolio company and global provider of science-backed branded and functional ingredients, to sell its portfolio of botanical extracts, vitamins and minerals, and food enhancement activities, including its range of natural colors and antioxidants and certain localized flavor activities in Peru. The portfolio serves a broad range of food, beverage and nutritional end markets through a comprehensive selection of customized solutions. “These businesses are highly respected, and we are confident they will continue to thrive under the ownership of SuanNutra and Carbyne,” said Erik Fyrwald, CEO IFF. “This transaction is another step in optimizing our portfolio and reinforces our focus on our core innovation-led businesses — Taste, Scent and Health & Biosciences — where we see the greatest opportunities to drive

NIQ Appoints Irina Stoian as Chief AI Commercial Officer20.7.2026 12:45:00 CEST | Press release

New executive role strengthens NIQ’s AI strategy and advances the company’s position as a trusted intelligence infrastructure powering AI-driven commerce NIQ today announced that Irina Stoian has joined the company as Chief AI Commercial Officer, a newly created role designed to accelerate NIQ’s enterprise AI commercial strategy and help clients turn the company’s AI capabilities into business impact and growth. Stoian will help align Product, Technology, Commercial, Partnerships, and Marketing around a unified AI growth strategy. Her remit includes shaping commercial AI offerings, strategic partnerships, pricing and business models, and deeper integration of NIQ capabilities into client workflows. The appointment builds on NIQ’s broader AI strategy, which positions the company as a trusted intelligence infrastructure powering AI-driven commerce. Across its AI portfolio, including ConnectAI, NIQ Optiq™, and NIQ Cadence™, NIQ is expanding how clients access trusted data, intelligence, a

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye